Ionis Pharmaceuticals, Inc.
Modulators of MALAT1 expression
Last updated:
Abstract:
The present embodiments provide methods, compounds, and compositions useful for inhibiting MALAT1 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with MALAT1.
Status:
Grant
Type:
Utility
Filling date:
27 Feb 2020
Issue date:
22 Mar 2022